- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following Registration Statements:
| (1) | Registration Statement (Form S-3 No. 333-233434) of NantKwest, Inc. for the registration of common stock, preferred stock, warrants, debt securities and units, |
| (2) | Registration Statement (Form S-4 No. 333-252232) of NantKwest, Inc. for the registration of common stock to be issued in connection with the merger with ImmunityBio, Inc., |
| (3) | Registration Statement (Form S-8 No. 333-205942) pertaining to the 2014 Equity Incentive Plan and 2015 Equity Incentive Plan, |
| (4) | Registration Statement (Form S-8 No.333-233082) pertaining to the 2015 Equity Incentive Plan as Amended and Restated, and |
| (5) | Registration Statement (Form S-8 No. 333-243725) pertaining to the 2015 Equity Incentive Plan as Amended and Restated; |
of our report dated March 4, 2021, with respect to the consolidated financial statements of NantKwest, Inc. included in this Annual Report (Form 10-K) of NantKwest, Inc. for the year ended December 31, 2020.
/s/ Ernst & Young LLP
Los Angeles, California
March 4, 2021